Element Biosciences, a dynamic startup based in San Diego, is making waves in the world of gene sequencing by introducing a groundbreaking device that can read DNA at an unprecedented cost. This innovative company is set to compete directly with industry leader Illumina, offering a high-throughput sequencing device that significantly undercuts the pricing of existing technologies.
A Game-Changing Device
On Thursday, Element Biosciences launched the VITARI, a benchtop sequencing device capable of delivering an entire genome for just $100. This is a remarkable reduction, considering Illumina’s NovaSeq, which offers similar capabilities at $200 per genome. Not only does the VITARI come at half the price, but it also boasts a compact design without compromising on the quality of lab-grade readings.
Matthew Kellinger, Element’s co-founder and vice president of biochemistry, expressed the company’s ambition to elevate the standards within the sequencing field. He highlighted a period of stagnation in the industry prior to Element’s inception, stating that the lack of competition has hindered advancements.
The Founders’ Vision
Element Biosciences was established in 2017 by three former Illumina executives: Molly He, the CEO; Michael Previte, the chief technology officer of advanced research; and Kellinger himself. Their collective vision was to disrupt the existing paradigm of gene sequencing and foster innovation in this critical field.
Currently, Element and Illumina are embroiled in legal disputes, with claims of antitrust violations and patent infringements exchanged between the two companies. This rivalry underscores the intense competition in the gene sequencing market, which is crucial for advancements in genetic research and therapies.
Growing Demand for Gene Sequencing
The need for effective gene-sequencing technology has surged as scientists increasingly rely on vast genetic data to investigate and potentially treat genetic disorders. Kristen Jepsen, director of the IGM Genomics Center at UC San Diego, emphasized the correlation between the number of genomes analyzed and the potential for significant discoveries. Enhanced access to sequencing technology could accelerate the search for cures.
Element’s VITARI is primarily aimed at biotechnology firms, large pharmaceutical companies, and academic institutions that require substantial sequencing capabilities. Despite the competitive pricing from both Element and Illumina, many labs still find themselves spending about $400 per genome, demonstrating the complexities of the market.
The Economics of Sequencing
The cost per genome is influenced by the volume of genomes being sequenced, similar to bulk purchasing at wholesale stores. Abraham Palmer, a professor at UC San Diego, noted that sequencing has effectively become a commodity, with lower costs driving broader access. By merging affordable equipment with economical sequencing options, Element is poised to make a significant impact on the industry.
Palmer also pointed out that budget constraints often dictate sample sizes in research. As sequencing costs decrease, researchers can afford to conduct larger studies that tackle more complex questions, ultimately advancing scientific understanding.
Rapid Evolution in Gene Sequencing
Just a few years ago, achieving genome sequencing for $1,000 was a notable achievement. The swift decline in costs highlights the rapid technological advancements within the field, as described by Kellinger. The pace of innovation suggests that the future of gene sequencing could be even more transformative.
Expansion and Future Prospects
Element Biosciences has grown significantly since its founding and currently employs over 400 people, with a substantial number residing in the local San Diego area. With the introduction of the VITARI device, the company anticipates further expansion, although specific hiring plans remain undisclosed.
In its recent Series D funding round, Element raised over $277 million, achieving a valuation of $1 billion. Although the company has yet to reach profitability, Kellinger expressed optimism about their trajectory toward becoming self-sustaining and hinted at the potential for an initial public offering (IPO) in the future.
Conclusion
Element Biosciences stands at the forefront of a new era in gene sequencing, challenging established giants with innovative, cost-effective solutions. As the competition heats up, the implications for scientific research and medical advancements are profound. With its ambitious vision and robust funding, Element is poised to reshape the landscape of genomics, making significant strides toward a future where gene sequencing is accessible and affordable for all.
- Element Biosciences has introduced a revolutionary sequencing device, VITARI, priced at $100 per genome.
-
The company, founded by former Illumina executives, aims to disrupt the gene sequencing market.
-
Legal disputes between Element and Illumina highlight the competitive nature of the industry.
-
Lower sequencing costs could enable larger studies and faster scientific discoveries.
-
Element has raised over $277 million, positioning itself for future growth and potential IPO.
Read more → www.sandiegouniontribune.com